Patients Excluded from Study 600 pts with 644 eyes accessed for eligibility 78 pts with 122 eyes excluded 522 pts included in study each contributing 1 eye 44 bilateral pts with each eye group D or E 30 pts received extensive pre-enucleation treatment 2 pts had non-tumor enucleation 2 pts died from chemo toxicity 1 anterior chamber hemorrhage? 1 atrophy w/o chemo 3 plaque 6 PPV 17 pts with IAC 2 radio 1 stem cell Factors to consider: pathologic staging, time from diagnosis to enu, neoadjuvant chemo, adjuvant chemo Dependent variable: mortality. 1 immunotherapy

Mortality and Pathology of Patients with D eyes 600 pts with 644 eyes accessed for eligibility 78 pts with 122 eyes excluded 522 pts included in study each contributing 1 eye 180 D eyes 342 E eyes 120 neoadjuvant chemo 60 no neoadjuvant chemo 5 dead (4.2%) 14 lost (11.7%) 0 dead (0%) 10 lost (16.7%) 103 (85%) 5 (4%) 2 (2%) 4 (3%) 3 (3%) 0 (0%) pT1 pT2a pT2b pT3a pT3b pT3c pT4 42 (70%) 7 (12%） 0 (0%） 0 (0%) 11 (18%) Kruscal-Walis Non-parametric test.

Mortality and Pathology of Patients with E eyes 600 pts with 644 eyes accessed for eligibility 78 pts with 122 eyes excluded 522 pts included in study each contributing 1 eye 342 E eyes 191 D eyes 128 neoadjuvant chemo 214 no neoadjuvant chemo 8 dead (3.7%) 27 lost (12.6%) 7 dead (5.5%) 28 lost (21.9%) 100 (78%) 5 (4%) 1 (1%) 11 (9%) 2 (1%) 4 (3%) pT1 pT2a pT2b pT3a pT3b pT3c pT4 126 (59%) 16 (7%) 5 (2%) 3 (1%) 52 (24%) 1 (1%) 12 (6%)

Relationship between neoadjuvant chemo cycle and pathology for staged D&E Eyes Low Risk Pathology (LRP): pT1 and pT2 High Risk Pathology (HRP): pT3 and pT4

Relationship between neoadjuvant chemo cycle and mortality After Controlling for Adjuvant Chemo (Kaplan Mier Survival Analysis)